Postexposure Chemoprophylaxis for Occupational Exposures to the Human Immunodeficiency Virus
- 10 March 1999
- journal article
- review article
- Published by American Medical Association (AMA) in JAMA
- Vol. 281 (10), 931-936
- https://doi.org/10.1001/jama.281.10.931
Abstract
Postexposure chemoprophylaxis is now recommended for health care workers who experience certain kinds of occupational exposures to the human immunodeficiency virus (HIV) in the workplace. Substantial information has emerged that supports but does not prove the efficacy of antiretroviral agents in preventing HIV infection after occupational exposure. This article reviews the data that have accrued in the past 8 years that bear directly on this question and describes a systematic approach to the clinical management of health care workers occupationally exposed to HIV.Keywords
This publication has 38 references indexed in Scilit:
- Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: Implications for HIV primary infectionNature Medicine, 1997
- Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways.JCI Insight, 1997
- The role of skin dendritic cells in the initiation of human immunodeficiency virus infectionAmerican Journal Of Medicine, 1997
- HIV: Dendritic cells as embers for the infectious fireCurrent Biology, 1996
- Acutely Infected Langerhans Cells Are More Efficient than T Cells in Disseminating HIV Type 1 to Activated T Cells Following a Short Cell-Cell ContactAIDS Research and Human Retroviruses, 1995
- Arguments Against the Chemoprophylactic Use of Zidovudine Following Occupational Exposure to the Human Immunodeficiency VirusClinical Infectious Diseases, 1993
- Use of Zidovudine Following Occupational Exposure to Human Immunodeficiency VirusClinical Infectious Diseases, 1992
- Prophylactic Zidovudine after Occupational Exposure to the Human Immunodeficiency Virus: An Interim AnalysisThe Journal of Infectious Diseases, 1989
- Occupational Risk of the Acquired Immunodeficiency Syndrome among Health Care WorkersNew England Journal of Medicine, 1986
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985